Register Login
Register to leave comments
  • News bot June 16, 2026, 11:35 a.m.

    📋 ACUMEN PHARMACEUTICALS, INC. (ABOS) - Clinical Trial Update

    Filing Date: 2026-06-16

    Accepted: 2026-06-16 07:34:21

    Event Type: Clinical Trial Update

    Event Details:

    ACUMEN PHARMACEUTICALS, INC. (ABOS) Announces Clinical Trial Update ACUMEN PHARMACEUTICALS, INC. (ABOS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: submission, delivered
    • Diseases/Conditions: a stable
    • Collaboration: Development Candidates
      • expected in late 2026
      • targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in AD. Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD. About ALTITUDE-AD (Phase 2) Initiated in 2024
      • targeting blood-brain barrier-penetrating technology, termed J-Brain Cargo®. By selecting these two candidates, the Company is expanding its optionality by nominating a bispecific antibody derived from sabirnetug as well as one based on a novel, next generation AβO-selective antibody with differentiated properties, known as ACU234. “The nomination of these candidates marks an important step forward in our effort to bring meaningful new treatment options to patients with Alzheimer’s disease,” said Jim Doherty, President and Chief Development Officer of Acumen. “By leveraging JCR’s J-Brain Cargo® alongside our oligomer-selective antibodies, we’re building a differentiated portfolio of bispecific antibodies designed to overcome the challenges of delivering therapeutics across the blood-brain barrier for the treatment of this devastating disease. We are advancing IND-enabling activities toward a mid-2027

    🔬 Clinical Development Pipeline (ACUMEN PHARMACEUTICALS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo Other Phase PHASE1 Alzheimer Disease ClinicalTrials.gov
    ACU193 Other Phase PHASE1 Alzheimer Disease ClinicalTrials.gov
    Ipilimumab Other Phase PHASE1 Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) ClinicalTrials.gov
    Nivolumab Other Phase PHASE1 Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) ClinicalTrials.gov
    DRP-104 Other Phase PHASE1 Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) ClinicalTrials.gov
    DNAJB1-PRKACA Peptide Vaccine Other Phase PHASE1 Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) ClinicalTrials.gov
    atezolizumab Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Durvalumab Other Phase PHASE1 Fibrolamellar Hepatocellular Carcinoma ClinicalTrials.gov
    Sabirnetug + rHuPH20 Other Phase PHASE1 Alzheimer Disease ClinicalTrials.gov
    sabirnetug (ACU193) Other Phase PHASE1 Alzheimer Disease ClinicalTrials.gov
    sabirnetug Other Phase PHASE2 Alzheimer Disease ClinicalTrials.gov
    Diclofenac DRUG Phase PHASE3 Osteo Arthritis of the Knee ClinicalTrials.gov
    Lubiprostone DRUG Phase PHASE3 Chronic Idiopathic Constipation ClinicalTrials.gov
    Placebo oral capsule DRUG Phase PHASE2 Cystic Fibrosis ClinicalTrials.gov
    LAU-7b DRUG Phase PHASE2 Cystic Fibrosis ClinicalTrials.gov
    Placebo for 3 cycles OTHER Phase PHASE2 Long COVID ClinicalTrials.gov
    LAU-7b for 1 cycle, then placebo DRUG Phase PHASE2 Long COVID ClinicalTrials.gov
    LAU-7b for 3 cycles DRUG Phase PHASE2 Long COVID ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ACUMEN PHARMACEUTICALS, INC.
    • Ticker Symbol: ABOS

Search

News categories